Authors
Laurence Albiges, A Ari Hakimi, Wanling Xie, Rana R McKay, Ronit Simantov, Xun Lin, Jae-Lyun Lee, Brian I Rini, Sandy Srinivas, Georg A Bjarnason, Scott Ernst, Lori A Wood, Ulka N Vaishamayan, Sun-Young Rha, Neeraj Agarwal, Takeshi Yuasa, Sumanta K Pal, Aristotelis Bamias, Emily C Zabor, Anders J Skanderup, Helena Furberg, Andre P Fay, Guillermo De Velasco, Mark A Preston, Kathryn M Wilson, Eunyoung Cho, David F McDermott, Sabina Signoretti, Daniel YC Heng, Toni K Choueiri
Publication date
2016/10/20
Journal
Journal of Clinical Oncology
Volume
34
Issue
30
Pages
3655-3663
Publisher
American Society of Clinical Oncology
Description
Purpose
Obesity is an established risk factor for clear cell renal cell carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be more indolent. We investigated the clinical and biologic effect of body mass index (BMI) on treatment outcomes in patients with metastatic RCC.
Methods
The impact of BMI (high BMI: ≥ 25 kg/m2 v low BMI: < 25 kg/m2) on overall survival (OS) and treatment outcome with targeted therapy was investigated in 1,975 patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and in an external validation cohort of 4,657 patients. Gene expression profiling focusing on fatty acid metabolism pathway, in The Cancer Genome Atlas data set, and immunohistochemistry staining for fatty acid synthase (FASN) were also investigated. Cox regression was undertaken to estimate the association of BMI with OS, adjusted for the IMDC …
Scholar articles
L Albiges, AA Hakimi, W Xie, RR McKay, R Simantov… - Journal of Clinical Oncology, 2016